[go: up one dir, main page]

CL2015003211A1 - Synergistic combination of paracetamol / celecoxib for the treatment of inflammatory pain. - Google Patents

Synergistic combination of paracetamol / celecoxib for the treatment of inflammatory pain.

Info

Publication number
CL2015003211A1
CL2015003211A1 CL2015003211A CL2015003211A CL2015003211A1 CL 2015003211 A1 CL2015003211 A1 CL 2015003211A1 CL 2015003211 A CL2015003211 A CL 2015003211A CL 2015003211 A CL2015003211 A CL 2015003211A CL 2015003211 A1 CL2015003211 A1 CL 2015003211A1
Authority
CL
Chile
Prior art keywords
paracetamol
celecoxib
treatment
inflammatory pain
synergistic combination
Prior art date
Application number
CL2015003211A
Other languages
Spanish (es)
Inventor
Medellin Jorge Fernando Cantu
Original Assignee
More Pharma Corp S De R L De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52279400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by More Pharma Corp S De R L De C V filed Critical More Pharma Corp S De R L De C V
Publication of CL2015003211A1 publication Critical patent/CL2015003211A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINACIÓN FARMACEUTICA SINERGÍSTICA DE PARACETAMOL/CELECOXIB Y SU USO PARA EL TRATAMIENTO DEL DOLOR INFLAMATORIO.PHARMACEUTICAL SYNERGISTIC COMBINATION OF PARACETAMOL / CELECOXIB AND ITS USE FOR THE TREATMENT OF INFLAMMATORY PAIN.

CL2015003211A 2013-07-11 2015-10-30 Synergistic combination of paracetamol / celecoxib for the treatment of inflammatory pain. CL2015003211A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2013/055710 WO2015004505A1 (en) 2013-07-11 2013-07-11 Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain

Publications (1)

Publication Number Publication Date
CL2015003211A1 true CL2015003211A1 (en) 2016-04-29

Family

ID=52279400

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003211A CL2015003211A1 (en) 2013-07-11 2015-10-30 Synergistic combination of paracetamol / celecoxib for the treatment of inflammatory pain.

Country Status (8)

Country Link
CL (1) CL2015003211A1 (en)
CR (1) CR20160021A (en)
CU (1) CU24440B1 (en)
DO (1) DOP2016000008A (en)
EC (1) ECSP16005679A (en)
MX (1) MX366118B (en)
PE (2) PE20160239A1 (en)
WO (2) WO2015004505A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147780B2 (en) * 2020-02-24 2021-10-19 Algia Pharma, Llc Multidrug pain management package
PE20251234A1 (en) * 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V CELECOXIB-ACETAMINOPHEN COMBINATION WITH ENHANCED STABILITY AND PROCEDURE FOR ITS PREPARATION
PE20251233A1 (en) 2023-10-05 2025-04-29 Laboratorios Silanes S A De C V MULTIACTIVE TABLET FOR THE TREATMENT AND CONTROL OF SEVERE CHRONIC PAIN AND PREPARATION METHOD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003208485B2 (en) * 2002-02-19 2009-05-28 Adcock Ingram Limited Pharmaceutical combinations of COX-2 inhibitors and opiates
GB0423103D0 (en) * 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents

Also Published As

Publication number Publication date
MX366118B (en) 2019-06-27
CU20160002A7 (en) 2016-06-29
MX2015013911A (en) 2015-12-08
PE20170305A1 (en) 2017-04-21
CU24440B1 (en) 2019-09-04
PE20160239A1 (en) 2016-05-13
WO2015004505A1 (en) 2015-01-15
WO2015004634A3 (en) 2015-04-09
WO2015004634A2 (en) 2015-01-15
DOP2016000008A (en) 2016-03-15
CR20160021A (en) 2016-04-08
ECSP16005679A (en) 2017-08-31

Similar Documents

Publication Publication Date Title
CL2016002027A1 (en) Cyclopropylamine as an inhibitor of lsd1
CL2016001609A1 (en) Pharmaceutical compositions comprising azd9291.
CL2016000153A1 (en) Glioxamide substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis b
NI201700034A (en) INDAZOLES SUBSTITUTED WITH BENZYL AS BUB1 INHIBITORS.
CL2016000807A1 (en) Amino heteroaryl benzamides as kinase inhibitors.
CL2015002658A1 (en) Derivatives of 2,3-disubstitute 1- acyl-4-amino-1,2,3,4-tetrahydroquiniline and its use as bromodomain inhibitors
MX378273B (en) ACTIVE COMPOUNDS TOWARDS BROMODOMAINS.
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
MX2015003140A (en) ENZALUTAMIDE FORMULATIONS.
MX377340B (en) SOLID SOLUTION COMPOSITIONS AND USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES.
MX386935B (en) PRODRUGS OF FUMARATES AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES.
PL3381451T3 (en) PHARMACEUTICAL COMPOSITION USED FOR REDUCTION OF LOCALIZED ADIPOSITE TISSUES AND USE OF THE PHARMACEUTICAL COMPOSITION
CL2015002180A1 (en) Combination therapy for the treatment of nosocomial pneumonia
CU20170018A7 (en) RORC2 PIRROLOPIRIDINE MODULATORS REPLACED WITH METHYL AND TRIFLUOROMETILO
CL2015002897A1 (en) Bace1 inhibitors
GT201600027A (en) RORC2 INHIBITORS AND THEIR METHODS OF USE
CL2016003074A1 (en) Compounds derived from 2-oxy-2-phenyl-n-5-pyrrolidin-3-ylamino-1,3,4-thiadiazol-2-ylacetamide, pharmaceutical composition gls1 inhibitors and their use to treat cancer.
CL2015003019A1 (en) Biaromatic antibacterial derivatives
IL253619A0 (en) Thermotherapy of active ingredients with high potency
PT2859896T (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DISTURBLES
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
MX374385B (en) APILIMOD FOR USE IN THE TREATMENT OF MELANOMA.
MX2018005987A (en) HETEROCICLICAL COMPOUNDS FOR THE TREATMENT OF DISEASES.
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX375318B (en) DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLORINE KYNURENINE.